TIDMAVO
RNS Number : 0283S
Advanced Oncotherapy PLC
12 March 2021
12 March 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
New study shows the potential superiority of LIGHT for resistant
cancers
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment called
LIGHT systems (LIGHT), today announces that it has demonstrated the
potential capability and superiority of LIGHT in "biologically
enhanced particle therapy(1) " to treat resistant cancers, which
are responsible for most relapses and one of the major causes of
death in cancer(2) .
The Company's findings build on research at the Mayo Clinic
which demonstrated the benefits of combining proton therapy with
targeted small molecule damage repair inhibitors. In a study
recently published in the American Association for Cancer
Research's journal Cancer Research(1) , the Mayo Clinic
demonstrated that cancer cells with defects in their DNA repair
pathways - such as resistant cancers - are more effectively killed
using proton therapy combined with a damage repair inhibitor(3)
.
The developers at the Mayo Clinic have named this new process
for "biologically enhanced particle therapy", LEAP. The ability to
deliver a LEAP treatment is predicated on the ability of the proton
therapy system to deposit intense radiation in a microscopic area
of the tumour, such as the DNA molecules. The amount of energy
deposited per length at a micrometer level - also called dLET - is
therefore an important parameter for optimising treatment plans and
treating resistant cancers.
The Board of Directors and the Medical Advisory Board of
Advanced Oncotherapy believe that LEAP is a significant step
forward in the application of proton therapy in the treatment of
cancers. Subsequently, the Company has demonstrated the capability
of LIGHT to bring the new LEAP treatment to patients with resistant
cancers(4) . To do so, the Company used data generated by LIGHT and
its proprietary treatment planning system to assess the LEAP effect
in a patient with triple negative breast cancer(5) for a smaller
target partial breast irradiation and whole breast irradiation. The
three major conclusions of this study are as follows:
-- dLET is currently not a parameter used in conventional
treatment plan systems. However, the proprietary treatment planning
system of LIGHT has been tailor-made to take into account dLET,
hence offering a more optimised LEAP treatment.
-- The maximum achieved dLET values observed with LIGHT within
the target for both of the cases considered are significantly
higher compared to cyclotron systems which are representative of
legacy proton systems.
-- In comparison to cyclotron systems, the resulting LIGHT LEAP
plans indicate greater conformity.
These results support the superior features of LIGHT, namely the
ability to optimise the treatment plan such that the highly dense
ionisation occurs at the tumour site and deliver a significantly
smaller proton beam in comparison to legacy proton therapy systems.
This is expected to pave the way for treating resistant cancers in
a more effective way.
Jonathan Farr, Chief Clinical Officer at Advanced Oncotherapy,
said :
"Innovation in cancer is occurring at a pace never seen before,
which has resulted in many technological breakthroughs, as
evidenced with the development of FLASH, a particularly exciting
field which holds great promises for treating patients in one
single visit. Following the ground-breaking results published by
the Mayo Clinic, LEAP represents another paradigm shift in cancer
treatment. This highlights the role of proton therapy in
combination with specific DNA repair inhibitors as a
technology-enabler for personalised treatment based on the
patient's tumour biology.
"Our LIGHT system, due to its smaller beam size compared to
legacy systems and its ability to deposit a greater level of
radiation damage in a micro-target volume, is ideally suited to
accelerate this trend and to further contribute to the development
of personalised medicines. This is exciting news for patients with
resistant cancers."
- ENDS -
Notes for editors
1 - Inhibition of ATM induces hypersensitivity to proton
irradiation by upregulating toxic end joining; Qin Zhou, Michelle
E. Howard, Xinyi Tu, Qian Zhu, Janet M. Denbeigh, Nicholas B.
Remmes, Michael G. Herman, Chris J. Beltran, Jian Yuan, Patricia T.
Greipp, Judy C. Boughey, Liewei Wang, Neil Johnson, Matthew P.
Goetz, Jann N. Sarkaria, Zhenkun Lou and Robert W. Mutter; Cancer
Res February 17 2021 DOI: 10.1158/0008-5472.CAN-20-2960
2 - For example, 30%-55% of patients with non-small cell lung
cancer (NSCLC) relapse and die from the disease afterwards
(European Respiratory Journal 2016 47: 374-378; DOI:
10.1183/13993003.01490-2015). The 50%-70% of ovarian
adenocarcinomas reoccur within 1 year after surgery and associated
chemotherapy (Ushijima K. (2010). Treatment for recurrent ovarian
cancer-at first relapse. Journal of oncology, 2010, 497429.
https://doi.org/10.1155/2010/497429).
3 - Proton therapy, a form of radiotherapy, relies on DNA damage
(strand breaks) to kill cancer cells like other forms of
radiotherapy but the targeted anti-tumour dose can be much higher
with protons, sparing normal tissues. Damage to one of the two DNA
strands can sometimes be repaired in the cancer cell, leading to
unwanted cancer cell survival and disease progression. Specific
genes, including ATM, BRCA1 and BRCA2, have an essential role in
this DNA repair pathway and this can occur in hereditary tumour
syndromes with genetic predispositions, or arise just in tumours
themselves. The mutations also result in markedly increased
susceptibility to a variety of cancers. For example, women with
BRCA1 mutation have as much as an 85% lifetime risk of developing
triple-negative breast cancer. Clinical research has also shown
that ATM mutations - which make the DNA repair mechanism less
effective - confer exceptional responses to radiation therapy, and
hence can be used as a novel mutation-based marker of
radiosensitivity.
4 - This study was undertaken by Advanced Oncotherapy using the
LIGHT system beam model. Before the LIGHT system can be used for
patient treatment it will be subject to 510(k) clearance by the US
Food and Drug Administration as well as conformity assessment(s) in
the different regions in which Advanced Oncotherapy is planning to
market the system.
5 - Triple negative breast cancers represent about 10-15% of
breast cancers (American Cancer Society). Patients demonstrate the
absence of oestrogen receptor, progesterone receptor and HER2
expression.
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656
Amrit Nahal / Matt Butlin (Sales and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDGGDXLUBDGBB
(END) Dow Jones Newswires
March 12, 2021 02:00 ET (07:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024